UNITED GUARDIAN INC - 10-Q Summary (Q1 2026)
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026. United Guardian Inc. operates as a single segment manufacturer of specialty cosmetic, personal care, sexual wellness ingredients, and healthcare products (including pharmaceuticals and medical lubricants). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $2,872,222 | $2,481,127 |
| Net Income | $818,902 | $560,895 |
| Earnings Per Share (Basic/Diluted) | $0.18 | $0.12 |
| Operating Income | $642,449 | $610,922 |
| Operating Margin | 22.4% | 24.6% |
| Cash from Operations | $604,536 | $322,080 |
| Cash & Equivalents (End of Period) | $735,854 | $1,269,212 |
| Total Assets | $12,699,481 | $13,108,579 |
| Total Liabilities | $1,797,147 | $1,876,567 |
| Working Capital | $10,344,756 | $10,532,076 |
| Current Ratio | 8.1:1 | 7.3:1 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% ($391,095) driven by a 24% increase in pharmaceutical sales (Renacidin and Clorpactin) and a 21% increase in cosmetic ingredients sales.
- Profitability: Net income rose 46% year-over-year. This was significantly boosted by $303,133 in settlement income from a contract manufacturer regarding a prior facility shutdown, which was not present in Q1 2025.
- Margins: Cost of sales as a percentage of net sales increased from 45% to 50% due to a higher mix of pharmaceutical products, which have higher tolling costs compared to in-house manufactured goods.
- Cash Flow: Operating cash flow nearly doubled to $604,536. However, cash and cash equivalents decreased by $515,243 due to dividend payments of $1.15 million and net investing activities.
- Dividends: The company declared and paid a dividend of $0.25 per share in Q1 2026, down from $0.35 per share in Q1 2025.
Outlook, Risks, and Unusual Items
- Unusual Item: The $303,133 settlement income is a non-recurring item. Management expects to receive an additional ~$35,000 in product value from this settlement in Q2 2026.
- Strategic Initiatives: In January 2026, the company signed a distribution agreement with Brenntag Specialties for its Natrajel sexual wellness line in North America and France. Additionally, Renacidin was approved for inclusion on two major Pharmacy Benefit Manager formularies starting in 2026.
- Risks:
- Concentration Risk: Four distributors (three pharmaceutical, one cosmetic) accounted for 75% of gross sales and accounts receivable in Q1 2026.
- Supply Chain: Three vendors accounted for 83% of raw material purchases. The company relies on a single contract manufacturer for Renacidin.
- Trade Policy: Ongoing geopolitical tensions and U.S. tariff changes pose risks to raw material costs and global supply chains.
- Guidance: No specific numerical guidance was provided. Management expects the effective tax rate to remain at approximately 21% for the fiscal year.
Investor Verification Checklist
- Verify the sustainability of the 24% pharmaceutical sales growth independent of the one-time settlement income.
- Monitor the impact of the new Brenntag distribution agreement on the sexual wellness segment revenue in upcoming quarters.
- Assess the risk exposure related to the four key distributors representing 75% of sales.
- Review the trend in Cost of Sales (currently 50%) to ensure it does not compress operating margins further as pharmaceutical sales volume increases.
- Confirm the status of the remaining $35,000 settlement value expected in Q2 2026.